SLFN11 and head and neck squamous cell carcinoma: In contrast, the sensitivity to the non-DNA-damaging drug docetaxel, which is widely used for induction chemotherapy in HNSCC (21), was not altered, regardless of the expression of SLFN11 in the five cell lines.